ACTR3

Across TCGA pan-cancer cohorts, ACTR3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACTR3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ACTR3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ACTR3 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

GBM, LUAD, and PDAC are the cancer types where ACTR3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.256	0.555	<.001	17	view →
LUAD	OS	Median	II,III,IV	0.474	0.808	.004	16	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
OV	DFS	Median	All	1.000	0.660	.013	8	view →
CCRCC	OS	Tertile	All	0.652	1.000	.018	8	view →
HNSC	OS	Tertile	All	0.953	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACTR3–GBM (OS)

Open the GBM breakdown →